Lantheus posts Q2 2026 results, pulls guidance amid pending Curium merger

Lantheus Holdings reported second-quarter 2026 financial results on August 6, 2026, in the middle of a pending sale of the company. The company announced on August 3, 2026 that it had entered into a definitive agreement to merge with Curium, under which Curium US Holdings LLC would acquire all outstanding shares in an all-cash transaction with a total value of up to approximately $8.0 billion.¹

Under the deal terms, Curium US Holdings LLC will pay $102.50 per share in cash at closing, plus non-transferable contingent value rights that could add up to $12.00 per share more depending on whether specified commercial milestones for Lantheus products are met through 2030, bringing total potential per-share consideration to $114.50.¹ Lantheus' board has unanimously approved the transaction.¹ The companies said the combination is meant to build a radiopharmaceutical business spanning diagnostics and therapeutics, with reach into more than 70 countries.¹

Because of the pending deal, Lantheus withdrew its previously issued full-year 2026 financial guidance and did not hold an earnings call to discuss the quarter.¹

On the numbers themselves, worldwide revenue rose 2.7% to $388.2 million versus the same period in 2025.¹ By product line, PYLARIFY sales fell 4.1% to $240.4 million,¹ Neuraceq brought in $39.6 million,¹ and DEFINITY sales grew 5.2% to $88.3 million.¹

On liquidity, cash and cash equivalents stood at $593.3 million as of June 30, 2026, up from $359.1 million at the end of 2025,¹ and the company has access to up to $750.0 million under a revolving credit line.¹

For process on the merger, Lantheus said it intends to file a preliminary and definitive proxy statement, which will be sent to stockholders ahead of a special meeting on the acquisition.¹